Cargando…
A 23‐Gene Classifier urine test for prostate cancer prognosis
Autores principales: | Guo, Jinan, Johnson, Heather, Zhang, Xuhui, Feng, Xiaoyan, Zhang, Heqiu, Simoulis, Athanasios, Wu, Alan HB, Xia, Taolin, Li, Fei, Tan, Wanlong, Johnson, Allan, Dizeyi, Nishtman, Abrahamsson, Per‐Anders, Kenner, Lukas, Chen, Lingwu, Zhong, Wanmei, Xiao, Kefeng, Persson, Jenny L., Zou, Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919118/ https://www.ncbi.nlm.nih.gov/pubmed/33784002 http://dx.doi.org/10.1002/ctm2.340 |
Ejemplares similares
-
Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients
por: Guo, Jinan, et al.
Publicado: (2021) -
Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up
por: Johnson, Heather, et al.
Publicado: (2020) -
Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification
por: Guo, Jinan, et al.
Publicado: (2020) -
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016) -
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)